| Literature DB >> 25180496 |
Gisela Cipullo Moreira1, José Paulo Cipullo1, Luiz Alberto Souza Ciorlia1, Cláudia Bernardi Cesarino1, José Fernando Vilela-Martin1.
Abstract
INTRODUCTION: Metabolic syndrome (MS) is a set of cardiovascular risk factors and type 2 diabetes, responsible for a 2.5-fold increased cardiovascular mortality and a 5-fold higher risk of developing diabetes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25180496 PMCID: PMC4152120 DOI: 10.1371/journal.pone.0105056
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic, anthropometric and lifestyle characteristics of studied population.
| Characteristics | N | % | N | % corrected for the population | ||
| Gender | Male | 667 | 49.7 | 211 | 23.3 | |
| Female | 702 | 50.3 | 256 | 22.7 | ||
| Socioeconomic status | AB | 288 | 17.8 | 92 | 22.2 | |
| C | 584 | 45.4 | 195 | 21.5 | ||
| DE | 497 | 36.8 | 180 | 25.2 | ||
| Education (schooling years) | <11 years | 989 | 60.4 | 363 | 27.7 | |
| ≥11 years | 380 | 39.6 | 104 | 15.9 | ||
| BMI | Normal-weight | 538 | 44.2 | 75 | 7.6 | |
| Overweight | 511 | 32.7 | 196 | 23.7 | ||
| Obese | 320 | 23.1 | 196 | 51.6 | ||
| Physical Activity | Inactive | 924 | 66.9 | 353 | 26.1 | |
| Active | 445 | 33.1 | 114 | 16.7 | ||
All the data are corrected for the total population of city. MS = Metabolic Syndrome; BMI = Body Mass Index.
Figure 1Prevalence of Metabolic Syndrome according to age.
It was observed that the prevalence of MS increased with aging years without a linear increase, but with a significant difference among age groups (p<0.0005). The percentage of individuals with MS in each age group was: 14.2% for 18–39 years, 25.6% for 40–49 years, 38.2% for 50–59 years, 40.4% for 60–69 years and 42.6% for those aged ≥70 years.
Figure 2Prevalence of Homa Index+ and Metabolic Syndrome.
The figure shows the prevalence of positive HOMA index according to age in individuals with (MS+ = clear bars) and without (MS− = dark bars) metabolic syndrome. The calculation of the HOMA index was performed in 841 individuals, because the insulin value was not determined in all the participants. It was observed that in subjects with MS+, in all the ages, the prevalence of positive HOMA index was always higher than in individuals without MS. MS: Metabolic Syndrome.
Figure 3Distribution of HDL-c levels in relation to alcohol consumption.
The individuals were divided in according to alcohol consumption into the 3 categories: no alcohol consumption (dotted line), moderate alcohol consumption (≤210 grams/week; dashed line) and high alcohol consumption (>210 grams/week; continuous line). It was observed an association between moderate and/or high alcohol consumption with HDL-c level normal or higher (p<0.0005), while individuals who did not consume alcohol showed a higher percentage of low HDL-C level. The analysis of HDL-c in relation to alcohol consumption was performed by means of bootstrap simulation method.
Figure 4Prevalence of Metabolic Syndrome components according to gender.
The evaluation of individuals with metabolic syndrome (MS) showed that there was a different prevalence of MS components according to gender (men = dark bars; women = clear bars). Among the population with MS, 85.0% of them showed high blood pressure (85.2% in men and 84.8% in women). It was observed that 83.1% had low HDL-c levels (81.9% in men and 84.2% in women), while 82.5% had waist measurement above normal (91.7% in women and 73.1% in men). The prevalence of changes in TG levels was 69.0% (76.6% in men and 61.6% in women). Levels of fasting glucose ≥100 mg/dL occurred in 36.4% of the subjects (36.0% in males and 36.7% in females). Blood pressure (BP), HDL-c: HDL-cholesterol, Waist: waist circumference, TG: Triglycerides, PGL: plasma glucose level.
Prevalence of the metabolic syndrome in developing countries.
| Author/year | Country/region and urban/rural area | Prevalence (%) | Age (yr) | Sample (n) | Criterion for diagnosis | ||
| Male | Female | Male | Female | ||||
| Podang J et al, 2013 | Thailand | 18.2 | 10.3 | ---- | 1875 | 669 | NCEP-ATPIII |
| Jaipakdee J et al, 2013 | Thailand | 25.1 | 35–60 | 628 | 2176 | Joint Statement 2009: (IDF, NHLBI, AHA, WHF, IAS, IASO) | |
| Tamang HK et al, 2013 | Nepal | 76.9 | 26–90 | 221 (total) | NCEP-ATPIII | ||
| Sy RG et al, 2014 | Philippines | 19.7 | 25.6 | 20–50 | 3072 (total) | IDF | |
| NCEP-ATPIII | |||||||
| Gupta et al, 2007 | North India (urban) | 22.9 | 31.6 | >20 | 532 | 559 | NCEP-ATPIII |
| Deepa et al, 2007 | South India (urban) | 23.2 | ≥20 | 23505 (total) | WHO | ||
| 18.3 | NCEP-ATPIII | ||||||
| 25.8 | IDF | ||||||
| Chow et al, 2008 | India (rural) | 32.5 | 23.9 | ≥30 | 4535 (total) | Modified NCEP-ATPIII | |
| Xi B et al, 2013 | China | 21.3 | ≥18 | 7488 (total) | NCEP-ATPIII | ||
| 18.2 | IDF | ||||||
| Liu M et al, 2013 | China | 50.4 (2001) | 60–95 | 943 | 1391 (2001) | Joint Statement 2009: (IDF, NHLBI, AHA, WHF, IAS, IASO) | |
| 58.1 (2010) | 848 | 1254 (2010) | |||||
| Xu S et al, 2014 | China | 29 - Rural | ≥20 | 3297 | Joint Statement 2009: (IDF, NHLBI, AHA, WHF, IAS, IASO) | ||
| 25.9 - Urban | |||||||
| You L et al, 2014 | China (Mongolian Area) | 36.7 | 17.8 | 20–80 | 809 | 617 | Joint Statement 2009: (IDF, NHLBI, AHA, WHF, IAS, IASO) |
| Al-Daghri NM et al, 2013 | Saudi Arabia | 39 (total) | 19–60 | 87 | 98 | IDF | |
| 24 | 55 | ||||||
| Shahini N et al, 2013 | Turkey | 35 | 33.6±6.8 mean±SD | 160 (total) | NCEP-ATPIII | ||
| Onat A et al, 2013 | Turkey | 53 | ≥40 | 796 (total) | NCEP-ATPIII | ||
| Esmailzadehha N et al, 2013 | Iran | 28 | 20–78 | 529 | 578 | WHO | |
| 26.2 | NCEP-ATPIII (2001) | ||||||
| 30.6 | NCEP-ATPIII (2004) | ||||||
| 34.2 | IDF | ||||||
| 33 | AHA/NHLBI | ||||||
| 39.3 | Joint Statement 2009 | ||||||
| De Carvalho Vidigal F et al, 2013 | Brazil (10 studies) | 29.6 | 19–64 | 3334 | 5171 | NCEP-ATPIII | |
| (14.9–65.3) | |||||||
| Saad MA et al, 2014 | Brazil | 51.9 | >60 | 63 | 180 | WHO modified | |
| 45.2 | NCEP-ATPIII | ||||||
| 64.1 | IDF | ||||||
| 69.1 | Joint Statement 2009 | ||||||
| Del Brutto OH et al, 2013 | Ecuador | 55.7 | ≥40 | 517 (total) | IDF | ||
| Moreira GC et al, 2014 | Brazil | 23.3 | 22.7 | ≥40 | 667 | 702 | Joint Statement 2009 |
NCEP-ATPIII = National Cholesterol Education Program-Adult Treatment Panel III; WHO = World Health Organization; IDF = International Diabetes Federation; AHA = American Heart Association; NHLBI = National Heart, Lung, Blood Institute; WHF = World Heart Federation; IAS = International Atherosclerosis Society; and IASO = International Association for the Study of Obesity.
Joint Statement 2009: (IDF, NHLBI, AHA, WHF, IAS, IASO).
SD = standard deviation.
* present study.